Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
ALS Data For Verdiperstat Expected In 2022
Executive Summary
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
You may also be interested in...
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant
With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.